updated chart, page-3144

Investing dollars are a little stretched currently as we pick off our watch list bargains, I think a lot of us are in the same situation where you look for a sign to lean in more. If we were the only speculative biotech on the ASX being brutalised I would be a little more on edge.

The market is still very much risk off and if you don't have a product that is about to enter or corner a market, or a product in demand in the market, then the market is being very harsh currently and will be until this economic cycle runs its course. Money in the bank is paying good and safe dividends and cash is at a premium.

That said, as I mentioned above, there were some green shoots of volume recently and this has been as good as any other indicator for PTX that news is coming. So since the last quarterly outlined the company appointments bringing in corporate expertise, along with potential partners showing interest and evaluating Cellpryme, I would be thinking with the relative silence since then that the company will have something more than speculation to announce on such partnerships before the next reporting period. The company was fairly bullish on those statements highlighting that this partner interest was notwithstanding the current cautious environment. I get the feeling such a partnership will open other more lucrative doors.

Now we wait.